Download PDF
Nuklearmedizin 1976; 15(04): 183-184
DOI: 10.1055/s-0038-1624958
Originalarbeiten — Original Articles
Schattauer GmbH

57Co-Hematoporphyrin Accumulation by Experimental Tumors

57Co-Hematoporphyrinanreicherung in experimentellen Tumoren
L. J. Anghileri
1   Aus der Inneren Klinik und Poliklinik — Tumorforschung (Direktor: Prof. Dr. C. G. Schmidt) des Universitätsklinikums der GHS Essen
,
M. Heidbreder
1   Aus der Inneren Klinik und Poliklinik — Tumorforschung (Direktor: Prof. Dr. C. G. Schmidt) des Universitätsklinikums der GHS Essen
,
R. Mathes
1   Aus der Inneren Klinik und Poliklinik — Tumorforschung (Direktor: Prof. Dr. C. G. Schmidt) des Universitätsklinikums der GHS Essen
› Author Affiliations
Further Information

Publication History

Received:05 March 1976

Publication Date:
11 January 2018 (online)

    Permissions and Reprints

Summary

The in vivo distribution of 57Co-hematoporphyrin in adenocarcinoma BW10232-bearing mice has been studied. Tumor-bearing and normal animals exhibit similar patterns of radioactivity accumulation. Twenty-four hours after the administration of the radiocompound the ratios tumor to blood and tumor to muscle indicate a potential value of this radioactive porphyrin for the detection of some types of tumor.

Die in vivo-Verteilung von 57Co-Hematoporphyrin in Adenokarzinom BW10232-tragenden Mäusen wurde untersucht. Tumortragende und normale Tiere zeigen ähnliche Anreicherungen von Radioaktivität. Vierundzwanzig Stunden nach der Verabreichung der radioaktiven Verbindung weist das Verhältnis Tumor zu Blut und Tumor zu Muskel auf einen möglichen Nutzen dieses radioaktiven Porphyrins für die Erkennung einiger Tumortypen hin.

 

  • References

  • 1 Sanderson D. R, Fontana R. S, Lipson R. L, Baldes E. J. Hematoporphyrin as a diagnostic tool. Cancer 1972; 30: 1368.
    CrossrefPubMedGoogle Scholar
  • 2 Gregorie H. B, Horger E. O, Ward J. L, Green J. F, Richards T, Robertson H. C, Stevenson T. B. Hemato-porphyrin-derivative fluorescence in malignant neoplasms. Ann. Surg 1968; 167: 820.
    CrossrefPubMedGoogle Scholar
  • 3 Lipson R. I, Baldes E. J, Gray M. J. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967; 20: 2255.
    CrossrefPubMedGoogle Scholar
  • 4 Lipson R. L, Baldes E. J, Olsen A. M. The use of a derivate of hematoporphyrin in tumor detection. J. Natl. Cancer Inst 1961; 26: 1.
    PubMedGoogle Scholar
  • 5 Peck G. C, Mack H. P, Holbrook W. A, Figge F. H. J. Use of hematoporphyrin fluorescence in biliary and cancer surgery. Am. Surg 1955; 167: 181.
    Google Scholar
  • 6 Granelli S. G, Diamond I, McDonald A. F, Wilson C. B, Nielsen S. L. Photochemotherapy of glioma cells by visible light and hematoporphyrin. Cancer Res 1975; 35: 2567.
    PubMedGoogle Scholar
  • 7 Figge F. H. J, Weiland G. S, Manganiello O. J. Cancer detection and therapy. Affinity of neoplastic, embryonic and traumatized tissues for porphyrins and metalloporphyrins. Proc. Soc. Exp. Biol. Med 1948; 68: 640.
    CrossrefPubMedGoogle Scholar
  • 8 Bases R. E. Distribution of Cu64-labeled copper protoporphyrin after injection into normal and tumor-bearing mice. Quarterly Progress Report Oct. 1 to Dec. 31, 1954 (BNL 326), Brookhaven National Laboratory. 1954: 45-46.
    Google Scholar
  • 9 Bases R, Brodie S. S, Rubenfeld D. Attempts at tumor localization using Cu64-labeled copper porphyrins. Cancer 1967; 11: 259.
    Google Scholar
  • 10 Smetana H. Studies on photodynamic action: II, fate of hematoporphyrin after parenteral administration; III, influence of sensitizer on photooxidation of tissues. J. Biol. Chem 1938; 125: 741.
    Google Scholar
  • 11 Anghileri L. J. In vivo distribution of radioactive chromic phosphate: Influence of the particle size and route of injection. Int. J. Appl. Radiat. & Isot 1965; 16: 623.
    Google Scholar